HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Root Wellness Provides Update Following Self-Regulatory Case That Resulted In FTC Referral

Executive Summary

Root Wellness execs address the company’s scrape with the Direct Selling-Self Regulatory Council and resulting referral to the Federal Trade Commission.

You may also be interested in...



FTC’s Health Products Guidance: Attorneys Discuss Insistence On RCTs, Implications For Businesses

The updated and expanded guidance embodies the US Federal Trade Commission’s enforcement approach for more than a decade, identifying randomized clinical trials as the competent and reliable scientific evidence needed to back health-related claims. Attorneys from Kelley Drye & Warren, Lathrop GMP and Amin Talati Wasserman weigh in.

BBB Unit Loses Patience With Root Wellness, Refers Supplement Direct Seller To FTC

In September 2021, the DSSRC recommended Root Wellness remove health claims made about dietary supplement products on its website and social media pages, including those of independent sales reps. After asking for evidence of progress in July, the Direct Selling Self-Regulatory Council is flagging the case to the Federal Trade Commission.

Responsibility For Distributors’ Claims At Root Of Supplement Direct Seller’s Advertising Review

After the DSSRC recommended that Root Wellness remove health claims from its advertising in 2021, the direct seller has not made efforts to remove the claims that its ambassadors have made on social media.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel